Glycyrrhetinic acid modified MOFs for the treatment of liver cancer
- 28 May 2020
- journal article
- research article
- Published by IOP Publishing in Nanotechnology
- Vol. 31 (32), 325602
- https://doi.org/10.1088/1361-6528/ab8c03
Abstract
Liver cancer remains a major cause of cancer-related death across the globe. Nano medicines have emerged as promising candidates to improve liver cancer chemotherapy. In this study, a glycyrrhetinic acid (GA) modified metal-organic framework-based drug delivery system (GA-MOFs) was developed to enhance the liver targeting ability of 5-FU. The physicochemical properties of GA-MOFs regarding particle size, size distribution and morphology were evaluated. The results showed that the obtained 5-FU@GA-MOFs had an octahedral structure, a uniform particle size distribution, and a diameter of similar to 200 nm. In vitro release experiments demonstrated that 5-FU@GA-MOFs exhibited a pH-dependent release pattern. MTT assays indicated that 5-FU-loaded GA-MOFs showed greater cytotoxicity towards HepG2 cells when compared to 5-FU alone at the same dose. In vivo tissue distribution demonstrated that the 5-FU@GA-MOFs significantly increased the accumulation of 5-FU in the liver. In vivo imaging analysis further manifested the liver targeting ability of GA-MOFs. Taken together, these results suggested that GA-modified MOFs showed promising potential as liver-targeting nanocarriers for the delivery of anti-tumor drugs.Keywords
Funding Information
- Natural Science Foundation of Liaoning Province (20180510016, 2019-MS-153)
This publication has 48 references indexed in Scilit:
- Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapyAsian Journal of Pharmaceutical Sciences, 2019
- A Pharmacogenomic Landscape in Human Liver CancersCancer Cell, 2019
- Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reducedColloids and Surfaces B: Biointerfaces, 2019
- Liver cancer: A leading cause of cancer death in the United States and the role of the 1945–1965 birth cohort by ethnicityJHEP Reports, 2019
- Glycyrrhetinic Acid Functionalized Nanoparticles for Drug Delivery to Liver CancerJournal of Biomedical Nanotechnology, 2018
- Application of zirconium MOFs in drug delivery and biomedicineCoordination Chemistry Reviews, 2018
- (Fe)MIL-100-Met@alginate: a hybrid polymer–MOF for enhancement of metformin's bioavailability and pH-controlled releaseNew Journal of Chemistry, 2018
- Metal–Organic Framework (MOF)‐Based Drug/Cargo Delivery and Cancer TherapyAdvanced Materials, 2017
- Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptidesBiomaterials, 2013
- Hepatocellular carcinomaThe Lancet, 2012